Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation.
Moreno-Reyes. R R; Kerkhofs. M M; L'Hermite-Balériaux. M M; Thorner. M O MO; Van Cauter. E E; Copinschi. G G
Key Findings
- GHRP‑2 (1 µg/kg) caused a rapid, physiological‑range GH surge and a transient prolactin increase.
- No measurable change in total sleep time, REM, or especially slow‑wave (deep) sleep was observed.
- A non‑significant tendency toward more wakefulness in the first hour after injection was noted.
Practical Outcomes
- For biohackers aiming to boost deep sleep with GHRP‑2, this study suggests the peptide is ineffective for that purpose, even at doses that raise GH. It indicates that using GHRP‑2 solely for sleep enhancement is not supported by evidence, so protocols should focus on other strategies for improving slow‑wave sleep.
Summary
In a small study of healthy young men, a single late‑night dose of GHRP‑2 raised growth hormone levels but did not increase deep (slow‑wave) sleep. The peptide caused a brief rise in prolactin and a normal GH pulse, but sleep patterns stayed the same, with a slight, non‑significant trend toward more wakefulness right after the injection.
Abstract
A complex interrelationship exists between sleep and somatotropic activity. In humans, intravenous injections of growth hormone-releasing hormone (GHRH) given during sleep consistently stimulate slow-wave (SW) sleep, particularly when given in the latter part of the night. In the present study, the possible somnogenic effects induced under similar conditions by GH-releasing peptide (GHRP) were investigated in seven young healthy men. Bolus intravenous injections of GHRP-2 (1 microgram/kg body wt) or saline, in randomized order, were given after 60 s of the third rapid-eye-movement period. All GHRP injections were immediately followed by transient prolactin elevations and by GH pulses of a magnitude within or around the upper limit of the physiological range. Except for a nonsignificant tendency to increased amounts of wakefulness during the 1st h after the injection, no effects of GHRP-2 administration on sleep were detected. There was in particular no enhancement of SW sleep. Thus, in contrast to GHRH, late-night single injections of GHRP-2 at a dosage resulting in similar GH elevations have no stimulatory effects on SW sleep. The present data provide evidence against the involvement of the GHRP axis in human SW sleep regulation.
Study Information
pubmed
1998
10.1152/ajpendo.1998.274.5.e779